Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Context Therapeutics Inc.NASDAQ: CNTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $7.02M rose 102.6% year over year, ahead of the +46.4% change in trailing-twelve-month research & development. Sequentially, it fell 40.8% from the prior quarter. Over 3 fiscal years it compounded at +65.0% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +102.6% holds above the trailing-twelve-month pace of +46.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 31.86M USD
- Year-over-year change
- +40.3%
- 4-year CAGR
- +70.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.86M | +40.3% |
| FY2024 | 2024-12-31 | 22.7M | +27.7% |
| FY2023 | 2023-12-31 | 17.78M | +150.8% |
| FY2022 | 2022-12-31 | 7.09M | +86.4% |
| FY2021 | 2021-12-31 | 3.81M | — |
Research & Development vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +46.4% is the 2nd highest of 11, against a peer median of -18.9%.
- Over three fiscal years its annual growth of +65.0% compares with a peer median of -18.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M USD | -29.1% | +37.8% | — |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M USD | +23.4% | -23.7% | — |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $5.77M USD | -21.5% | -38.7% | — | |
| Peer median (excluding CNTX) | — | -18.9% | -18.0% | 6613.1% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M |
| Selling, General & Admin | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M |
| Operating Expenses | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| EBITDA | (7.44M) | (14.87M) | (23.95M) | (26.71M) | (36.11M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (10.53M) | (15.38M) | (25.07M) | (29.92M) | (39.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 64 | 547.27K | 1.16M | 3.2M | 3.38M |
| Interest Expense | 64.24K | 547.27K | 0 | 0 | 0 |
| Other Income / Expenses | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M |
| Income Before Tax | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| EPS (Diluted) | (3.69) | (0.93) | (1.50) | (0.46) | (0.38) |
| Weighted Avg Shares | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
| Weighted Avg Shares (Diluted) | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.